CN115068546B - 一种防治家禽肝病的中兽药口服液及其应用 - Google Patents
一种防治家禽肝病的中兽药口服液及其应用 Download PDFInfo
- Publication number
- CN115068546B CN115068546B CN202210621969.5A CN202210621969A CN115068546B CN 115068546 B CN115068546 B CN 115068546B CN 202210621969 A CN202210621969 A CN 202210621969A CN 115068546 B CN115068546 B CN 115068546B
- Authority
- CN
- China
- Prior art keywords
- parts
- oral liquid
- root
- preventing
- liver diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 239000007788 liquid Substances 0.000 title claims abstract description 46
- 244000144977 poultry Species 0.000 title claims abstract description 29
- 208000019423 liver disease Diseases 0.000 title claims abstract description 25
- 241000675108 Citrus tangerina Species 0.000 claims abstract description 35
- 241001116757 Pyrrosia lingua Species 0.000 claims abstract description 14
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 14
- 241000132012 Atractylodes Species 0.000 claims abstract description 13
- 241000972673 Phellodendron amurense Species 0.000 claims abstract description 12
- 239000009636 Huang Qi Substances 0.000 claims abstract description 11
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 10
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 10
- 240000001851 Artemisia dracunculus Species 0.000 claims abstract description 10
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 10
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 10
- 241000050051 Chelone glabra Species 0.000 claims abstract description 10
- 244000150195 Cyperus longus Species 0.000 claims abstract description 10
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 10
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 10
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract description 10
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 10
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 10
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 10
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 10
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000273 veterinary drug Substances 0.000 claims abstract description 10
- 244000236521 Bupleurum rotundifolium Species 0.000 claims abstract description 9
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 claims abstract description 9
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 235000018109 Cyperus longus Nutrition 0.000 claims abstract 3
- 244000075634 Cyperus rotundus Species 0.000 claims abstract 3
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 3
- 235000005010 Scirpus paludosus Nutrition 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- 239000000284 extract Substances 0.000 claims description 46
- 241000972672 Phellodendron Species 0.000 claims description 37
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 claims description 34
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 23
- 229920000053 polysorbate 80 Polymers 0.000 claims description 23
- 238000000605 extraction Methods 0.000 claims description 20
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 claims description 17
- 239000005792 Geraniol Substances 0.000 claims description 17
- 229940113087 geraniol Drugs 0.000 claims description 17
- 229940087305 limonene Drugs 0.000 claims description 16
- 235000001510 limonene Nutrition 0.000 claims description 16
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 claims description 15
- 108010053775 Nisin Proteins 0.000 claims description 15
- 238000009835 boiling Methods 0.000 claims description 15
- 235000010297 nisin Nutrition 0.000 claims description 15
- 239000004309 nisin Substances 0.000 claims description 15
- 239000000341 volatile oil Substances 0.000 claims description 14
- 241000245665 Taraxacum Species 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 238000002791 soaking Methods 0.000 claims description 13
- 238000011049 filling Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 11
- 238000007599 discharging Methods 0.000 claims description 9
- 241000219061 Rheum Species 0.000 claims description 8
- ODVWAQRULHSAML-HCUGZAAXSA-N (2e)-3,7-dimethylocta-2,6-dien-1-ol;ethanol Chemical compound CCO.CC(C)=CCC\C(C)=C\CO ODVWAQRULHSAML-HCUGZAAXSA-N 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 4
- 241000112528 Ligusticum striatum Species 0.000 claims description 4
- 240000004980 Rheum officinale Species 0.000 claims description 4
- 235000008081 Rheum officinale Nutrition 0.000 claims description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 4
- 235000011477 liquorice Nutrition 0.000 claims description 4
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 238000001256 steam distillation Methods 0.000 claims description 4
- 241000045403 Astragalus propinquus Species 0.000 claims description 2
- 235000006533 astragalus Nutrition 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 238000001647 drug administration Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 31
- 241000282414 Homo sapiens Species 0.000 abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 abstract description 3
- 229940088710 antibiotic agent Drugs 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 241000287828 Gallus gallus Species 0.000 description 43
- 235000013330 chicken meat Nutrition 0.000 description 43
- 230000000052 comparative effect Effects 0.000 description 26
- 230000000694 effects Effects 0.000 description 23
- 235000013594 poultry meat Nutrition 0.000 description 16
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 15
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 15
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 14
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 14
- 229960003321 baicalin Drugs 0.000 description 14
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 12
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 12
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 12
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 12
- 229940025878 hesperidin Drugs 0.000 description 12
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 12
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 12
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 244000144992 flock Species 0.000 description 11
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 9
- 229940093265 berberine Drugs 0.000 description 9
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 241001106477 Paeoniaceae Species 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 206010019842 Hepatomegaly Diseases 0.000 description 6
- 231100000678 Mycotoxin Toxicity 0.000 description 6
- 230000002421 anti-septic effect Effects 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 235000021050 feed intake Nutrition 0.000 description 6
- 239000002636 mycotoxin Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 210000000232 gallbladder Anatomy 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 3
- 235000019743 Choline chloride Nutrition 0.000 description 3
- 241001071795 Gentiana Species 0.000 description 3
- 206010019707 Hepatic rupture Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 229960003178 choline chloride Drugs 0.000 description 3
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 210000003746 feather Anatomy 0.000 description 3
- 238000009499 grossing Methods 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 241000202726 Bupleurum Species 0.000 description 2
- 241000218645 Cedrus Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- 206010041235 Snoring Diseases 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 239000010871 livestock manure Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 230000008558 metabolic pathway by substance Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- 241000561734 Celosia cristata Species 0.000 description 1
- 241000284156 Clerodendrum quadriloculare Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 241001480224 Heterodera Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001505935 Phalaenopsis Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 208000026555 breast adenosis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000000514 hepatopancreas Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及中药制备技术领域,提出了一种防治家禽肝病的中兽药口服液及其应用,一种防治家禽肝病的中兽药口服液配方,按照重量份包括以下组分:茵陈5~20份、车前子5~20份、石韦5~20份、黄芩5~30份、黄柏5~10份、大黄10~30份、川芎5~20份、白芍5~10份、蒲公英5~10份、甘草5~10份、陈皮5~20份、青皮5~10份、柴胡10~30份、香附5~10份、黄芪10~30份、白术10~30份。通过本发明中中兽药口服液的应用,解决了家禽肝失调达、肝郁气滞等问题,降低抗生素滥用,进一步保障了人类食品的安全。
Description
技术领域
本发明涉及中药制备技术领域,具体的,涉及一种防治家禽肝病的中兽药口服液及其应用。
背景技术
肝脏既是家禽体内最大的消化腺,又是体内物质代谢、能量代谢和物质转化最旺盛、功能最多样化的重要器官。其功能涉及物质代谢、生物转化、胆汁生成与分泌、凝血、内分泌调节和免疫等机能;还在体温维持、调节血液循环量、调节水在血管内外分布平衡中均起着非常重要的作用,因此肝脏是家禽体内的一个巨大的“化工厂”。近年来,家禽的腺肌胃炎高发,霉菌及霉菌毒素的危害越来越引起重视,而霉菌毒素进入家禽体内,除了对家禽的胃肠道直接腐蚀之外,侵害的最重要的靶器官就是肝脏;近年来各种混感发病率有加重趋势,肝肿大、肝破裂、肝硬化、不明原因的黄疸等症状多发,使得家禽肝脏不堪重负。
目前对家禽肝病治疗的方法主要是采取抗生素,对于弧菌性肝炎多用金霉素、强力霉素、红霉素、庆大、卡那、磺胺、呋喃、恩诺沙星等,五天一个疗程,由于常复发无论用何药都需坚持两个疗程;对于盲肠肝炎用药以甲硝唑、痢特灵为主,辅助治疗用维生素K3、维生素A,在病鸡转向康复时还要用左旋咪唑驱除异刺线虫。在家禽的肝病治疗上大量采取抗生素治疗会使抗生素药物效果变差,甚至无效;同时对人类也会带来较强的毒副作用,直接伤害身体,尤其是儿童的听力;大量杀灭体内正常细菌,致使菌群失调。
发明内容
本发明提出一种防治家禽肝病的中兽药口服液及其应用,解决了相关技术中的家禽肝失调达、肝郁等问题;降低抗生素滥用的问题,进一步保障了人类食品的安全。
本发明的技术方案如下:
一种防治家禽肝病的中兽药口服液,其特征在于,按照重量份包括以下组分:茵陈5~20份、车前子5~20份、石韦5~20份、黄芩5~30份、黄柏5~10份、大黄10~30份、川芎5~20份、白芍5~10份、蒲公英5~10份、甘草5~10份、陈皮5~20份、青皮5~10份、柴胡10~30份、香附5~10份、黄芪10~30份、白术10~30份。
作为进一步的技术方案,按照重量份包括以下组分:茵陈10~18份、车前子10~18份、石韦10~18份、黄芩15~25份、黄柏6~10份、大黄15~25份、川芎10~20份、白芍6~10份、蒲公英5~8份、甘草6~10份、陈皮7~18份、青皮6~10份、柴胡15~25份、香附6~10份、黄芪15~25份、白术15~25份。
作为进一步的技术方案,按照重量份包括以下组分:茵陈15份、车前子15份、石韦15份、黄芩20份、黄柏8份、大黄20份、川芎15份、白芍8份、蒲公英6份、甘草6份、陈皮15份、青皮8份、柴胡20份、香附8份、黄芪20份、白术20份。
一种防治家禽肝病的中兽药口服液的制备方法,包括以下步骤:
S1、按照所述的中兽药口服液的配方,称取各中药组分备用;
S2、以乙醇和香叶醇为提取剂制备黄柏提取液;
S3、采用水蒸气蒸馏法制备陈皮和青皮挥发油;
S4、将茵陈、车前子、石韦、黄芩、大黄、川芎、白芍、蒲公英、甘草、柴胡、香附、黄芪、白术采用水煎提法制备提取液,经过滤后得到混合提取液;
S5、将黄柏提取液取上清液进行低温减压浓缩,加乙醇制成得黄柏提取流浸膏,备用;
S6、将所述混合提取液进行低温减压浓缩得浓缩液,冷藏静置后离心,取上清液为混合提取浓缩液;
S7、上述混合提取浓缩液中加入黄柏提取流浸膏、陈皮和青皮挥发油、辅料进行配液,灌封、灭菌后得口服液成品;
所述步骤S2中,乙醇-香叶醇提取溶剂的质量为黄柏的10倍;乙醇与香叶醇的质量比为6:4;
所述步骤S7中,辅料为吐温-80、柠檬烯、乳酸链球菌素。
作为进一步的技术方案,所述步骤S2醇提法的条件为,将黄柏破碎成1~3cm的碎粒,添加乙醇-香叶醇提取溶剂,浸泡1h~2h,回流提取1~3h得到黄柏提取液。
作为进一步的技术方案,所述步骤S3水蒸气蒸馏法的条件为,将陈皮、青皮切制成细丝,按质量比加入5~10倍的水浸泡30~60min,然后加热蒸馏2~5h提取,收集挥发油,得到陈皮和青皮的挥发油。
作为进一步的技术方案,所述步骤S4水煎提法为,将茵陈、车前子、石韦、川芎、白芍、蒲公英、甘草、柴胡、香附、黄芪、白术、黄柏、陈皮、青皮,加水至超过药面2公分,浸泡30~60min,煮沸后,再微沸煎提60min,放出一煎药液;药渣再加入水至超过药面2公分,煮沸后,加入黄芩和大黄,再微沸煎煮60min,放出二煎药液;一煎药液与二煎药液合并,过滤得到混合提取液。
作为进一步的技术方案,所述步骤S6低温减压浓缩条件为,于60~70℃下真空浓缩成相对密度为1.01~1.05浓缩液,冷藏静置后离心,取清液为混合提取浓缩液。
作为进一步的技术方案,所述步骤S7为,在混合提取浓缩液中添加0.2wt%~0.4wt%吐温-80,再调pH5.0~6.0,然后添加0.05wt%~0.15wt%柠檬烯和0.20wt%~0.30wt%乳酸链球菌素;灌装机灌装完成后,进行灭菌,灭菌温度为100~121℃,灭菌时间为15~30min,制得中药口服液。
本发明还提出一种所述的防治家禽肝病的中兽药口服液在防治家禽肝病中的应用。
本发明的工作原理及有益效果为:
1、在中兽医中,肝主疏泄,肝病多因郁使然,多有气滞、血瘀、脾虚、癥积等证。根据方剂配伍组成的原则,本发明以柴胡、陈皮、川芎、香附、白芍为君药,柴胡为疏肝解郁第一要药,具有疏肝利胆、疏气解郁、升举阳气之效;陈皮、香附理气,川芎活血,相伍为用具有疏肝理气、活血化瘀之效;白芍具有养血柔肝之功;5味药材进行复配可以达到疏肝解郁、活血化瘀的功效。以黄芩、蒲公英、大黄、茵陈、车前子、石韦、黄柏为臣药,具有清热利湿、利水消肿、消除肝肿大的功效。以青皮、白术、黄芪为佐药,具有和中益气、健脾消食之功,同时防止肝病传变。甘草为之使,调和诸药。本发明的中药制剂是一个不可拆分的整体,每一味药材都在其中发挥着不可替代的作用,相辅相成,不仅发挥着各自的药效,还能提高其他药材的药效,减轻其他药材的副作用。
2、本发明的中药口服液针对鸡的霉菌毒素中毒、疏肝解郁、提食增料、肝胆破裂方面进行了应用,用药2~5天即可达到显著的治疗效果。
3、本发明人还意外的发现,将乙醇和香叶醇进行复配对黄柏中的小檗碱进行萃取,提高了黄柏流浸膏中小檗碱的含量;肝胆两者密不可分,相辅相成,柠檬烯的加入除具有防腐的作用外还具有利胆的作用;将乳酸链球菌素和柠檬烯进行复配,不仅提高了中药口服液的防腐效果,还能提高中药口服液的应用效果。
4、本发明对调节pH与添加吐温-80的先后顺序,以及吐温-80的添加量对中药口服液中的黄芩苷、芍药苷、橙皮苷含量的影响进行了研究,得到先加入0.4%的吐温-80,再调pH值为5.6~5.7时,黄芩苷、芍药苷、橙皮苷的含量最大。
附图说明
下面结合附图和具体实施方式对本发明作进一步详细的说明。
图1为吐温-80对黄芩苷含量的影响;
图2为吐温-80对芍药苷含量的影响;
图3为吐温-80对橙皮苷含量的影响;
图4为pH值对黄芩苷含量的影响;
图5为pH值对芍药苷含量的影响;
图6为pH值对橙皮苷含量的影响;
图7为先加吐温与先调pH的对比。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都涉及本发明保护的范围。
实施例1
一种防治家禽肝病的中兽药口服液的制备方法,包括以下步骤:
S1、称取茵陈15份、车前子15份、石韦15份、黄芩20份、黄柏8份、大黄20份、川芎15份、白芍8份、蒲公英6份、甘草6份、陈皮15份、青皮8份、柴胡20份、香附8份、黄芪20份、白术20份,备用。
S2、将黄柏破碎成约1cm的碎粒,添加乙醇和香叶醇,浸泡1h,回流提取2h,得到黄柏提取液,其中乙醇-香叶醇的质量为黄柏的10倍,乙醇与香叶醇的质量比为6:4。
S3、将陈皮、青皮切制成细丝,按质量比加入8倍的水浸泡60min,然后加热蒸馏3h提取,得到陈皮和青皮的挥发油。
S4、将剩余的其它药材加水至超过药面2公分,浸泡60min,煮沸后,再微沸煎提60min,放出一煎药液;药渣再加入水至超过药面2公分,煮沸后,加入黄芩和大黄,再微沸煎煮60min,放出二煎药液;一煎药液与二煎药液合并,过滤得到混合提取液。
S5、将黄柏提取液进行低温减压浓缩,低温减压浓缩条件为,于65℃下真空浓缩成相对密度为1.03浓缩液,制得黄柏醇提浸膏,添加75%乙醇溶剂溶解,配成60%黄柏流浸膏。
S6、将混合提取液进行低温减压浓缩,低温减压浓缩条件为,于65℃下真空浓缩成相对密度为1.03浓缩液,冷藏静置12h,在6500r/min下离心15min,取上清为混合提取浓缩液。
S7、混合提取浓缩液中加入60%黄柏流浸膏、陈皮和青皮挥发油,添加0.4wt%吐温-80,再调pH5.7,然后添加0.1wt%柠檬烯和0.25wt%乳酸链球菌素;灌装机灌装完成后,进行灭菌,灭菌温度为105℃,灭菌时间为20min,制得中药口服液。
实施例2
S1、称取茵陈20份、车前子5份、石韦20份、黄芩5份、黄柏10份、大黄30份、川芎5份、白芍10份、蒲公英5份、甘草5份、陈皮20份、青皮5份、柴胡5份、香附5份、黄芪10份、白术30份,备用。
S2、将黄柏破碎成约1cm的碎粒,添加乙醇和香叶醇,浸泡1h,得到黄柏提取液,乙醇-香叶醇的质量为黄柏的10倍,乙醇与香叶醇的质量比为6:4。
S3、将陈皮、青皮切制成细丝,按质量比加入8倍的水浸泡30min,然后加热蒸馏2h回流提取,得到陈皮和青皮的挥发油。
S4、将剩余的其它药材加水至超过药面2公分,浸泡30min,煮沸后,再微沸煎提60min,放出一煎药液;药渣再加入水至超过药面2公分,煮沸后,加入黄芩和大黄,再微沸煎煮60min,放出二煎药液;一煎药液与二煎药液合并,过滤得到混合提取液。
S5、将将黄柏提取液进行低温减压浓缩,低温减压浓缩条件为,于65℃下真空浓缩成相对密度为1.03浓缩液,制得黄柏醇提浸膏,添加75%乙醇溶剂溶解,配成60%黄柏流浸膏。
S6、将混合提取液进行低温减压浓缩,低温减压浓缩条件为,于65℃下真空浓缩成相对密度为1.03浓缩液,冷藏静置12h,在6500r/min下离心15min,取上清为混合提取浓缩液。
S7、混合提取浓缩液中加入60%黄柏流浸膏、陈皮和青皮挥发油,添加0.3wt%吐温-80,再调pH5.0,然后添加0.05wt%柠檬烯和0.20wt%乳酸链球菌素;灌装机灌装完成后,进行灭菌,灭菌温度为105℃,灭菌时间为15min,制得中药口服液。
实施例3
S1、称取茵陈5份、车前子20份、石韦5份、黄芩30份、黄柏5份、大黄10份、川芎20份、白芍5份、蒲公英10份、甘草10份、陈皮5份、青皮10份、柴胡30份、香附10份、黄芪30份、白术10份,备用。
S2、将黄柏破碎成约2cm的碎粒,添加乙醇和香叶醇,浸泡1.5h,得到黄柏提取液,乙醇-香叶醇的质量为黄柏的10倍,乙醇与香叶醇的质量比为6:4。。
S3、将陈皮、青皮切制成细丝,按质量比加入8倍的水浸泡40min,然后加热蒸馏3h回流提取,得到陈皮和青皮的挥发油。
S4、将剩余的其它药材加水至超过药面2公分,浸泡45min,煮沸后,再微沸煎提60min,放出一煎药液;药渣再加入水至超过药面2公分,煮沸后,加入黄芩和大黄,再微沸煎煮60min,放出二煎药液;一煎药液与二煎药液合并,过滤得到混合提取液。
S5、将黄柏提取液进行低温减压浓缩,低温减压浓缩条件为,于65℃下真空浓缩成相对密度为1.03提取液,制得黄柏醇提浸膏,添加75%乙醇溶剂溶解,配成60%黄柏流浸膏。
S6、将混合提取液进行低温减压浓缩,低温减压浓缩条件为,于65℃下真空浓缩成相对密度为1.03浓缩液,冷藏静置12h,在6500r/min下离心15min,取上清为混合提取浓缩液。
S7、混合提取浓缩液中加入60%黄柏流浸膏、陈皮和青皮挥发油,添加0.2wt%吐温-80,再调pH6.0,然后添加0.15wt%柠檬烯和0.30wt%乳酸链球菌素;灌装机灌装完成后,进行灭菌,灭菌温度为105℃,灭菌时间为30min,制得中药口服液。
对比例1
将实施例1中步骤S2的香叶醇替换成等量的乙醇。
对比例2
将实施例1中步骤S2的乙醇替换成等量的香叶醇。
对比例3
将实施例1中步骤S7的柠檬烯替换成等量的乳酸链球菌素。
对比例4
将实施例1中步骤S7的乳酸链球菌素替换成等量的柠檬烯。
试验例1
以实施例1为基准,将吐温-80的添加量分别调整为0wt%、0.1wt%、0.2wt%、0.3wt%、0.4wt%、0.5wt%,测定黄芩苷、芍药苷、橙皮苷的含量,研究吐温-80的添加量对黄芩苷、芍药苷、橙皮苷含量的影响,检测方法参见中国药典2020版《中华人民共和国药典》。
由图1可知,随着吐温-80含量的增加,黄芩苷含量先增后降,0.3wt%时黄芩苷含量最高;由图2可知,随着吐温-80含量的增加,芍药苷含量先降后升,0.5wt%时芍药苷含量最高;由图3可知,随着吐温-80含量的增加,橙皮苷含量先增后降,0.1wt%时芍药苷含量最高。综合考虑,吐温-80的最佳添加量为0.4wt%。
试验例2
以实施例1为基准,将pH分别调节为5.0、5.2、5.4、5.6、5.8、6.0,测定黄芩苷、芍药苷、橙皮苷的含量,研究不同pH对黄芩苷、芍药苷、橙皮苷含量的影响,检测方法参见中国药典2020版《中华人民共和国药典》。
由图4可知,随着pH值的增加,黄芩苷含量呈上升趋势,pH值为6.0时黄芩苷含量最高;由图5可知,随着pH值的增加,芍药苷含量呈下降趋势,pH为5.0时芍药苷含量最高;由图6可知,随着pH值含量的增加,橙皮苷含量先降后升再降,pH值为5.2时芍药苷含量最高。综合考虑,pH值的最佳区间为5.6~5.8。
试验例3
以实施例1为基准,分别测定先加吐温-80再调pH与先调pH再加吐温-80的情况下,黄芩苷、芍药苷、橙皮苷的含量,研究添加吐温-80与调节pH的先后顺序对黄芩苷、芍药苷、橙皮苷含量的影响,检测方法参见中国药典2020版《中华人民共和国药典》。
由图7可知,先加吐温-80优于先调pH值。
试验例4
采用紫外分光光度法分别取实施例1~3及对比例1~2中制得的黄柏提取液检测其中的小檗碱的浓度,检测方法参见中国药典2020版《中华人民共和国药典》。
实施例1与对比例3、4分别在25℃和55℃下放置8个月,跟踪测定菌落总数、大肠杆菌、黄色葡萄球菌、霉菌。菌落总数检测方法参照《GB4789.2-2016》、大肠杆菌检测方法参照《GB4789.3-2016》平板法、金黄色葡萄球菌检测方法参照《GB4789.10-2016》第二法、霉菌检测方法参照《GB4789.15-2016》。
表1实施例1~3和对比例1、对比例2中黄柏提取液中小檗碱的含量
实施例1和对比例3~4在25℃下放置八个月,菌落总数、大肠杆菌、金黄色葡萄球菌、霉菌均未检出。
表2实施例1和对比例3、对比例4在55℃放置下菌落总数的跟踪检测
实施例1 | 对比例3 | 对比例4 | |
15天 | - | - | - |
1个月 | - | - | - |
3个月 | - | - | - |
6个月 | - | - | - |
8个月 | - | 12CFU/mL | 9CFU/mL |
“-”为未检出。
表3实施例1和对比例3、对比例4在55℃放置下大肠杆菌的跟踪检测
实施例1 | 对比例3 | 对比例4 | |
15天 | - | - | - |
1个月 | - | - | - |
3个月 | - | - | - |
6个月 | - | - | - |
8个月 | - | 3CFU/mL | 2CFU/mL |
“-”为未检出。
表4实施例1和对比例3、对比例4在55℃放置下金黄色葡萄球菌的跟踪检测
实施例1 | 对比例3 | 对比例4 | |
15天 | - | - | - |
1个月 | - | - | - |
3个月 | - | - | - |
6个月 | - | - | - |
8个月 | - | - | - |
“-”为未检出。
表5实施例1和对比例3、对比例4在55℃放置下霉菌的跟踪检测
实施例1 | 对比例3 | 对比例4 | |
15天 | - | - | - |
1个月 | - | - | - |
3个月 | - | - | - |
6个月 | - | - | - |
8个月 | - | 6CFU/mL | 2CFU/mL |
“-”为未检出。
本发明的实施例与对比例相比,小檗碱含量为0.32~0.37mg/g,提高了黄柏提取液中小檗碱的含量,并且提高了防腐效果,其中实施例1是本发明的最佳实施例。
与实施例1相比,对比例1将香叶醇替换成等量的乙醇,对比例2将乙醇替换成等量的香叶醇,所得到的小檗碱含量均小于实施例1,说明单一的使用的乙醇或者单一的使用香叶醇,均不能提高香柏提取液中小檗碱的含量,可见只有在乙醇与香叶醇复配进行提取时才能提高香柏提取液中小檗碱的含量。与实施例1相比,对比例3将柠檬烯替换成等量的乳酸链球菌素,对比例4将乳酸链球菌素替换成等量的柠檬烯,得到的中药口服液的防腐效果均小于实施例1,从表2~5中可以得到乳酸链球菌素的防腐效果小于柠檬烯的防腐效果,但实施例1将乳酸链球菌素与柠檬烯进行复配,得到的中药口服液防腐效果高于对比例3、对比例4。可见,只有乳酸链球菌素与柠檬烯进行复配使用时,才可以提高中药口服液的防腐效果。
试验例5
将实施例1所制得的中药口服液针对鸡群的霉菌毒素中毒、疏肝解郁、提食增料、肝胆破裂进行应用。
应用1
品种:双A
日龄:20日龄
地区:山东省青岛市
试验方案:1.对两栋鸡舍的防控效果进行试验对比,每栋鸡舍1万只鸡除用药不同外,其它饲养条件均相同。
2.实施例1中制备的中药口服液(500mL/瓶)的用量:2瓶/天/10000只,连用5日;龙胆泻肝散剂,1g/只,连用5日。
3.一万只鸡使用实施例1制备的中药口服液进行对比试验,称“实施例1组”。
4.一万只鸡使用“龙胆泻肝”产品,做为“对照组”。
表6实施例1组与对照组试验指标
对比项目 | 实施例1组 | 对照组 |
死亡率 | 0.3% | 0.5% |
粪便对比 | 成形 | 稍稀,不成形 |
用药后采食量 | 平均2.8两/只 | 平均2.6两/只 |
剖检症状 | 肝脏大小及颜色正常 | 肝脏仍有肿大出血现象 |
40日龄后状况 | 后期长势好,羽毛顺 | 后期均匀度不行,羽毛差于前者 |
效果分析:“实施例1组”使用后效果明显优于“龙胆泻肝对照组”,死亡率明显下降,采食量上升,后期长势非常好。
应用2
品种:海兰褐
日龄:200日龄
地区:昌吉市
试验方案:1.对两栋鸡舍的防控效果进行试验对比,每栋鸡舍1万只鸡,除用药不同外,其他均相同。
2.实施例1制备的中药口服液(500mL/瓶)用法用量:1瓶/天/5000只,连用5日;“氯化胆碱”产品在基础饲料中添加8mg/kg氯化胆碱,连用5日。
3.一万只鸡使用“实施例1制备的中药口服液”进行对比试验,称“实施例1组”。
4.一万只鸡使用“氯化胆碱”产品,做为“对照组”。
表7实施例1组与对照组试验指标
对比项目 | 实施例1组 | 对照组 |
死亡率 | 隔天1只 | 每天两只 |
产蛋率 | 95% | 93% |
蛋重 | 0.067kg | 0.058kg |
采食量 | 平均2.4两/只 | 平均2.3两/只 |
效果分析:实施例1制备的中药口服液使用后的蛋重、产蛋率、鸡群状态明显优于对照组,且死淘率低于对照组。
应用3
山东临沂某鸡场,肉鸡240000羽,单栋养殖规模4万只,20日龄发病,每个棚1万只鸡,每个棚每日死亡22-28只,采食量较正常低10%,精神状态佳,毛乍不顺,鸡群呼噜,拉绿干粪,户主曾用双黄连+“囊杆净”治疗四天,无明显效果。24日龄时解剖肝脏发暗紫、肿大,脾脏肿大,肠道细,无粪便,腹气囊炎。
中医辨证分析:肝气不疏,肝亢脾虚,采食不增,气滞血瘀则肝淤血肿大;肝火上炎,拉绿干粪,鸡群腹膜炎,零星呼噜,治则清肝利胆,疏肝解郁,通肠通腑。
治疗方案:根据治疗选择,选择实施例1制备的中药口服液(500mL/瓶),每瓶兑水1800L,2瓶/天/10000只,连用4天。选用1个鸡棚进行试验。
用药回访:用药2天后死淘降到每日10-14只;用药3天后,采食量大幅增加,毛色也顺了。用药4天后,鸡群恢复正常,每日死亡2只,直到出栏没有继发细菌性疾病(大肠杆菌),也无绿粪、采食量下降、瘫痪的问题出现,鸡群成功出栏。
应用4
保定清苑某鸡场,饲养京粉六号35000只,自180日龄起,每日死淘20-28只,产蛋率94.7%有零星土黄色粪便。解剖呈现肝脏肿大,肝破裂,腹腔内有血水,有的肝脏上有星芒状坏死,肠道鼓气空虚,大群无明显症状。
中医辨证分析:肝主疏泄,疏泄气血,鸡群气机通畅,生产性能强健;疏泄毒素,促进霉菌毒素、药物毒素排出体外。当肝胆胃肠之气郁滞,肠道内的毒素蓄积排泄受阻,鸡群证见肝破裂肝肿大;鸡群证见土黄色粪便,黄为五脏脾的主色,综合分析是肝胆湿热致使肝亢脾虚,气滞血瘀。治则清肝利胆,疏肝解郁,柔肝养血,活血化瘀。
治疗方案:根据治疗选择,选择实施例1的制备的中药口服液(500mL/瓶),每瓶兑水1800L,2瓶/天/10000只,连用5天。
用药回访:用药3天后死淘降低到8只,蛋壳颜色比原来粉润;用药5天后鸡群死淘降低到2只,蛋壳质量比原来光亮,用药1周后蛋重增加了40多斤,产蛋率达到95.1%。
应用5
品种:海兰白
日龄:25日龄
临床症状:
1.鸡群死淘31只/天/10000只。
2.大群鸡精神基本正常,部分鸡精神欠佳,鸡冠萎缩、食欲不振,鸡群均匀度差。
3.部分鸡吐水,拉灰黑色稀便。
解刨症状:(1)肝脏肿大、边缘增厚呈黄色;(2)肝脏肿大、颜色呈暗红色;(3)腺胃水肿、肌胃胶质增生溃疡,肠道弥漫性陈旧出血,肠壁、肠系膜呈黑色。
诊断:霉菌毒素中毒
治疗方案:实施例1制备的中药口服液(500mL/瓶):3瓶/天/10000只,连用5天。
用后鸡群情况:1、使用2天后,鸡群精神好转,食欲增强,鸡群死淘降到15只/天。2.使用4天后鸡群死淘降到4只/天。3、使用5天后,鸡群恢复正常。
以上仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (8)
1.一种防治家禽肝病的中兽药口服液,其特征在于,原料为按照重量份的以下组分:茵陈5~20份、车前子5~20份、石韦5~20份、黄芩5~30份、黄柏5~10份、大黄10~30份、川芎5~20份、白芍5~10份、蒲公英5~10份、甘草5~10份、陈皮5~20份、青皮5~10份、柴胡10~30份、香附5~10份、黄芪10~30份、白术10~30份;
所述防治家禽肝病的中兽药口服液的制备方法,包括以下步骤:
S1、称取各中药组分备用;
S2、以乙醇和香叶醇为提取剂制备黄柏提取液;
S3、采用水蒸气蒸馏法制备陈皮和青皮挥发油;
S4、将茵陈、车前子、石韦、黄芩、大黄、川芎、白芍、蒲公英、甘草、柴胡、香附、黄芪、白术采用水煎提法制备提取液,经过滤后得到混合提取液;
S5、将黄柏提取液取上清液进行低温减压浓缩,加乙醇制成得黄柏提取流浸膏,备用;
S6、将所述混合提取液进行低温减压浓缩得浓缩液,冷藏静置后离心,取上清液为混合提取浓缩液;
S7、上述混合提取浓缩液中加入黄柏提取流浸膏、陈皮和青皮挥发油、辅料进行配液,灌封、灭菌后得口服液成品;
所述步骤S2中,乙醇-香叶醇提取溶剂的质量为黄柏的10倍,乙醇与香叶醇的质量比为6:4;
所述步骤S7中,辅料为吐温-80、柠檬烯、乳酸链球菌素。
2.根据权利要求1所述的一种防治家禽肝病的中兽药口服液,其特征在于,原料为按照重量份的以下组分:茵陈10~18份、车前子10~18份、石韦10~18份、黄芩15~25份、黄柏6~10份、大黄15~25份、川芎10~20份、白芍6~10份、蒲公英5~8份、甘草6~10份、陈皮7~18份、青皮6~10份、柴胡15~25份、香附6~10份、黄芪15~25份、白术15~25份。
3.根据权利要求2中所述的一种防治家禽肝病的中兽药口服液,其特征在于,原料为按照重量份的以下组分:茵陈15份、车前子15份、石韦15份、黄芩20份、黄柏8份、大黄20份、川芎15份、白芍8份、蒲公英6份、甘草6份、陈皮15份、青皮8份、柴胡20份、香附8份、黄芪20份、白术20份。
4.根据权利要求1所述的一种防治家禽肝病的中兽药口服液,其特征在于,所述步骤S2醇提法的条件为,将黄柏破碎成1~3cm的碎粒,添加乙醇-香叶醇提取溶剂,浸泡1h~2h,回流提取1~3h得到黄柏提取液。
5.根据权利要求1所述的一种防治家禽肝病的中兽药口服液,其特征在于,所述步骤S3水蒸气蒸馏法的条件为,将陈皮、青皮切制成细丝,按质量比加入5~10倍的水浸泡30~60min,然后加热蒸馏2~5h提取,收集挥发油,得到陈皮和青皮的挥发油。
6.根据权利要求1所述的一种防治家禽肝病的中兽药口服液,其特征在于,所述步骤S4水煎提法为,将茵陈、车前子、石韦、川芎、白芍、蒲公英、甘草、柴胡、香附、黄芪、白术,加水至超过药面2公分,浸泡30~60min,煮沸后,再微沸煎提60min,放出一煎药液;药渣再加入水至超过药面2公分,煮沸后,加入黄芩和大黄,再微沸煎煮60min,放出二煎药液;一煎药液与二煎药液合并,过滤得到混合提取液。
7.根据权利要求1所述的一种防治家禽肝病的中兽药口服液,其特征在于,所述步骤S6低温减压浓缩条件为,于60~70℃下真空浓缩成相对密度为1.01~1.05浓缩液,冷藏静置后离心,取清液为混合提取浓缩液。
8.根据权利要求1所述的一种防治家禽肝病的中兽药口服液,其特征在于,所述步骤S7为,在混合提取浓缩液中添加0.2wt%~0.4wt%吐温-80,再调pH5.0~6.0,然后添加0.05wt%~0.15wt%柠檬烯和0.20wt%~0.30wt%乳酸链球菌素;灌装机灌装完成后,进行灭菌,灭菌温度为100~121℃,灭菌时间为15~30min,制得中药口服液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210621969.5A CN115068546B (zh) | 2022-06-02 | 2022-06-02 | 一种防治家禽肝病的中兽药口服液及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210621969.5A CN115068546B (zh) | 2022-06-02 | 2022-06-02 | 一种防治家禽肝病的中兽药口服液及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115068546A CN115068546A (zh) | 2022-09-20 |
CN115068546B true CN115068546B (zh) | 2023-08-22 |
Family
ID=83248734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210621969.5A Active CN115068546B (zh) | 2022-06-02 | 2022-06-02 | 一种防治家禽肝病的中兽药口服液及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115068546B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1144668A (zh) * | 1995-03-17 | 1997-03-12 | 孙枫淦 | 肝肾宁 |
CN104383055A (zh) * | 2014-11-26 | 2015-03-04 | 南京市第二医院 | 一种治疗慢性乙型肝炎终末期肝病的药物及其制备方法 |
CN104840967A (zh) * | 2015-05-13 | 2015-08-19 | 上海中医药大学 | 一种含乙醇中药液体口服制剂的矫味方法 |
-
2022
- 2022-06-02 CN CN202210621969.5A patent/CN115068546B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1144668A (zh) * | 1995-03-17 | 1997-03-12 | 孙枫淦 | 肝肾宁 |
CN104383055A (zh) * | 2014-11-26 | 2015-03-04 | 南京市第二医院 | 一种治疗慢性乙型肝炎终末期肝病的药物及其制备方法 |
CN104840967A (zh) * | 2015-05-13 | 2015-08-19 | 上海中医药大学 | 一种含乙醇中药液体口服制剂的矫味方法 |
Also Published As
Publication number | Publication date |
---|---|
CN115068546A (zh) | 2022-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102961640A (zh) | 防治猪口蹄疫的药物及其制备方法 | |
CN104286422A (zh) | 一种高抗病性的复合家禽饲料添加剂 | |
CN104887890A (zh) | 一种治疗雏鸡白痢的药物组合物及其制备方法 | |
CN102552656A (zh) | 一种用于治疗鸡大肠杆菌病的中药组合物 | |
WO2020155318A1 (zh) | 一种治疗家畜细菌性呼吸道疫病的中药制剂及其生产工艺 | |
CN102526510A (zh) | 一种用于预防和治疗鸭病毒性肝炎的中药组合物 | |
CN103007111B (zh) | 一种治疗兔腹泻的中药制剂及其制备方法 | |
CN115068546B (zh) | 一种防治家禽肝病的中兽药口服液及其应用 | |
CN114886961A (zh) | 用于治疗/预防禽痛风的中药组合物及其制备方法、用途 | |
CN105250972A (zh) | 一种防治家禽腺胃炎的中药组合物及其制备方法和用途 | |
CN104208524A (zh) | 用于治疗仔猪痢疾的药物 | |
CN109432287B (zh) | 一种防治家禽气分热盛证的中药口服液及其制备方法 | |
CN114366770A (zh) | 一种七清败毒颗粒的制备方法 | |
CN105192430A (zh) | 预防鸡疾病的鸡饲料添加剂 | |
CN108904691A (zh) | 一种防治新城疫的清解合剂及其制备方法 | |
CN109125540A (zh) | 一种防治禽流感的藿香正气口服液及其制备方法 | |
CN103947893A (zh) | 一种用于防治鸭曲霉菌病的饲料、中药组合物和制备方法 | |
CN111920898B (zh) | 一种抗病毒处方及其制备方法 | |
CN115919951B (zh) | 一种中药组合物及其制备方法和应用 | |
CN106729589A (zh) | 治疗猪传染性胃肠炎的中药制剂及制备方法 | |
CN109464652B (zh) | 一种用于禽畜腹泻的组合物及其制备方法和应用 | |
CN106310226A (zh) | 一种防治仔猪下痢的中药复方制剂及制备方法 | |
CN106075283A (zh) | 一种提高阉割公鸡存活率的中药组合物、制备方法及应用 | |
CN106361902A (zh) | 一种防治家畜腹泻的中药组合物及其制备方法 | |
CN101209319A (zh) | 一种具有清热解毒、利水渗湿功效的复方中药颗粒剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |